Insights

Quantum Drug Design PolarisQB is a biotech startup leveraging quantum computing and AI to accelerate drug discovery, aiming to compress lead times from years to months. This presents a sales opportunity to engage early-stage biotechs and pharma teams seeking faster R&D timelines and a competitive edge.

QuADD Platform The QuADD platform represents a commercial SaaS offering for quantum-aided drug design, already announced and actively marketed. Target potential buyers include biotech firms and CROs looking for scalable AI-empowered discovery tools and real-time iteration capabilities.

Beta Program PolarisQB launched a beta program in 2025 to gather feedback from biotech companies, researchers, and academic groups. This indicates a ready pathway for pilots, co-development opportunities, and early-adopter discounts to de-risk initial deployments.

Strategic Partnerships Existing collaboration with Scientist.com signals openness to marketplace-style partnerships for outsourced research. This creates a channel strategy for sales teams to pursue integrative deals with research marketplaces and service providers.

IP and Licensing The company aims to build an IP portfolio of drug assets to license or sell, suggesting opportunities to cross-sell platform capabilities to licensors, biotech incubators, and pharma firms seeking access to novel drug design assets and expedited preclinical pipelines.

Similar companies to PolarisQB

PolarisQB Tech Stack

PolarisQB uses 8 technology products and services including HubSpot Analytics, iCIMS, WordPress, and more. Explore PolarisQB's tech stack below.

Media & News

PolarisQB's Email Address Formats

PolarisQB uses at least 1 email format:
PolarisQB Email FormatsExamplePercentage
FLast@polarisqb.comJDoe@polarisqb.com
100%

Frequently Asked Questions

What is PolarisQB's official website and social media links?

Minus sign iconPlus sign icon
PolarisQB's official website is polarisqb.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does PolarisQB generate?

Minus sign iconPlus sign icon
As of November 2026, PolarisQB's annual revenue is estimated to be $1M - $10M.

What is PolarisQB's SIC code and NAICS code?

Minus sign iconPlus sign icon
PolarisQB's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does PolarisQB have currently?

Minus sign iconPlus sign icon
As of November 2026, PolarisQB has approximately 8 employees across 2 continents, including North America and Europe. Key team members include Ceo And Co-Founder: S. K., Cto And Co-Founder: B. S. and Director Of Computational Chemistry: K. B. Explore PolarisQB's employee directory with LeadIQ.

What industry does PolarisQB belong to?

Minus sign iconPlus sign icon
PolarisQB operates in the Biotechnology Research industry.

What technology does PolarisQB use?

Minus sign iconPlus sign icon
PolarisQB's tech stack includes HubSpot Analytics, iCIMS, WordPress, Google Workspace, Google Cloud, WhatsApp Business, WP Engine and Piwik PRO Core.

What is PolarisQB's email format?

Minus sign iconPlus sign icon
PolarisQB's email format typically follows the pattern of FLast@polarisqb.com. Find more PolarisQB email formats with LeadIQ.

How much funding has PolarisQB raised to date?

Minus sign iconPlus sign icon
As of November 2026, PolarisQB has raised $2.1M in funding. The last funding round occurred on Dec 30, 2024 for $2.1M.

When was PolarisQB founded?

Minus sign iconPlus sign icon
PolarisQB was founded in 2020.
PolarisQB logo

PolarisQB

Biotechnology ResearchNorth Carolina, United States2-10 Employees

PolarisQB is a biotechnology research company based in Durham, North Carolina. It pursues drug design using a combination of quantum-inspired computation, artificial intelligence, machine learning, and personalized medicine to accelerate discovery efforts. The company aims to compress the preclinical lead time from about five years to four months and to produce up to one hundred drug blueprints per year to support real-time adaptability within the precision medicine landscape. It plans to build an intellectual property portfolio of drug assets that can be licensed, sold, or developed internally.

The company targets biotechnology companies, research institutions, and academic groups seeking faster, more adaptable drug discovery and improved predictive capabilities. In August 2025, PolarisQB launched QuADD, a platform for quantum-enabled drug discovery, marking a concrete product development milestone.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2020
Employees
2-10

Section iconFunding & Financials

  • $2.1M

    PolarisQB has raised a total of $2.1M of funding over 2 rounds. Their latest funding round was raised on Dec 30, 2024 in the amount of $2.1M as a Seed.

  • $1M - $10M

    PolarisQB's revenue is estimated to be in the range of $1M - $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.